产品编号 :
Cas No. :
CAS No. |
67-30-1 |
|---|---|
英文名称 |
2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid |
别名 |
3,3’,5,5’-tetraiodo-thyroaceticaci;3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)-benzeneaceticaci;3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)benzeneaceticacid;acide3,5,3’,5’-tetraiodothyroacetique;Levothyroxine – Impurity D;Liothyronine EP Impurity D;tetraiodothyroaceticacid;4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenylacetic acid |
标准英文名 |
2-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid |
分子式 |
C14H8I4O4 |
分子量 |
747.83 |
精确分子量 |
747.66 |
SMILES |
O=C(O)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1 |
标准SMILES |
OC1C(I)=CC(=CC=1I)OC1=C(I)C=C(CC(O)=O)C=C1I |
用途 |
Tetrac (Tetraiodothyroacetic acid) is a natural derivative of L-thyroxine (T4) and functions as an integrin receptor antagonist of thyroid hormones. It blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor on integrin αvβ3. Tetrac exhibits anti-angiogenic and anti-tumor activities. In vitro, Tetrac (0.01–1 μM; 2–6 days) induces anti-proliferation in HT-29 and HCT116 colorectal cancer cells regardless of K-RAS status. Tetrac (0.1 μM; 30 min) inhibits ERK1/2 activation in these cells, and this effect is reversed by pretreatment with an anti-integrin αvβ3 antibody. Additionally, Tetrac (0.1 μM; 24 h) suppresses expression of CCND1 and c-Myc while upregulating CASP2 and THBS1. In vivo, oral administration of Tetrac (35 μg/day for 40 days) delays tumor onset, inhibits tumor growth, and reduces integrin expression in murine models of ocular melanoma (B16F10 and B16LS9 cells), as evidenced by decreased S-100 and integrin staining levels. |
InChIKey |
PPJYSSNKSXAVDB-UHFFFAOYSA-N |
|
|
评论 |
|---|